Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by PoorOpinionon Feb 20, 2018 1:33pm

58 Views

Post# 27588505

RE:0.29 is holding so far

What you saying?

1) It's reached its pre-news high at 29?
or
2) It looks supported at 29 and may go higher?

If its the first I think its a bit early to make that call.

rtftech16 wrote: Chart tells me more buyers than sellers around 0.29 and more sellers than buyers around 0.30+ . I am sure it will stay at 0.29 bottom until news is out then its either up or down

Bullboard Posts

From now on, dynaCERT instead of Bitcoin or NVIDIA?